Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 221.52M P/E - EPS this Y 46.70% Ern Qtrly Grth 157,566.70%
Income 12.46M Forward P/E 27.44 EPS next Y 45.50% 50D Avg Chg -4.00%
Sales 149.54M PEG 4.21 EPS past 5Y -21.39% 200D Avg Chg 6.00%
Dividend N/A Price/Book 1.26 EPS next 5Y 6.00% 52W High Chg -14.00%
Recommedations 2.00 Quick Ratio 1.98 Shares Outstanding 57.48M 52W Low Chg 33.00%
Insider Own 7.32% ROA 2.62% Shares Float 8.96M Beta -
Inst Own 49.39% ROE 5.91% Shares Shorted/Prior 36.85K/45.04K Price 4.94
Gross Margin 40.39% Profit Margin 8.33% Avg. Volume 38,083 Target Price 12.00
Oper. Margin 10.70% Earnings Date May 8 Volume 11,175 Change -2.37%
About Kamada Ltd.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kamada Ltd. News
05/09/24 Kamada Ltd. (NASDAQ:KMDA) Q1 2024 Earnings Call Transcript
05/08/24 Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance
05/01/24 Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
05:46 AM KMDA: Double Digit Growth Anticipated in 2024 with $158 Million in Expected Revenues and $28 Million in Expected Adjusted EBITDA…
03/07/24 Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Earnings Call Transcript
03/06/24 Kamada Issues 2024 CEO Letter to Shareholders
03/06/24 Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
02/28/24 Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024
12/07/23 KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®
12/07/23 KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…
12/06/23 Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years
11/15/23 KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…
07:00 AM Kamada Reports Significant Increase in Sales and Profitability in the Third Quarter and Nine Month 2023; Reiterates 2023 Revenue and Profitability Guidance
11/08/23 Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023
10/16/23 Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data
10/10/23 Kamada Provides Corporate Update on its Israel Operations
08/30/23 Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds
08/21/23 KMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…
08/16/23 Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability Guidance
08/09/23 Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023
KMDA Chatroom

User Image epsguid Posted - 4 days ago

$KMDA reported earnings of $0.04, consensus was $0.06 via @eWhispers #epsmiss http://eps.sh/d/kmda

User Image Stock_Titan Posted - 4 days ago

$KMDA Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance https://www.stocktitan.net/news/KMDA/kamada-reports-strong-first-quarter-2024-financial-results-with-year-omx4jz2zbimh.html

User Image Stock_Titan Posted - 1 week ago

$KMDA Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024 https://www.stocktitan.net/news/KMDA/kamada-to-announce-first-quarter-2024-financial-results-and-host-qzdx0hkysbwr.html

User Image Fullratio Posted - 04/28/24

Healthcare sector stocks with high YoY EPS growth in Q4 2023: $KMDA $ROIV $OSUR

User Image NewMoon33 Posted - 04/14/24

$KMDA Stress levels are going up? Just visit www.Balticamber.nl And get your Authentic Baltic Amber! Start your healing today!

User Image fnm1988 Posted - 1 month ago

$KMDA There are rumors in Israel that KEDRION is planning a purchase or merger with KAMADA for trading on Nasdaq. I don't believe these rumors and even though I am invested in kmda from $5.6 I believe the stock will reach $10 this year without KEDRION rumors because of the big contract with KEDRION.

User Image cryptocurrency666 Posted - 1 month ago

$KMDA @kornsolana $korn

User Image LachlanLoughlin Posted - 1 month ago

I’ve made $93,111.27 (891.33%) with their alerts, Big thanks $KMDA to this chat room Make as much as you want.]🙌

User Image HarrisonWebster Posted - 1 month ago

I’ve made $93,111.27 (891.33%) with their alerts, Big thanks to this $KMDA chat room Make as much as you want.;😊

User Image StockScanners Posted - 1 month ago

$KMDA Looking for a bounce from 5-5.25,

User Image epsguid Posted - 2 months ago

$KMDA reported earnings of $0.09, consensus was $0.05 via @eWhispers #epsbeat http://eps.sh/d/kmda

User Image Stock_Titan Posted - 2 months ago

$KMDA Kamada Issues 2024 CEO Letter to Shareholders https://www.stocktitan.net/news/KMDA/kamada-issues-2024-ceo-letter-to-grhft3g9npci.html

User Image DonCorleone77 Posted - 2 months ago

$KMDA Kamada reports Q4 EPS 9c vs 7c last year Reports Q4 revenue $36.432M vs $45.439M last year. "We are extremely pleased with the strong financial and operational momentum we experienced through 2023, which allowed us to achieve our full-year guidance," said Amir London, Kamada's Chief Executive Officer. "Total revenues for 2023 were $142.5 million, representing record annual revenues and 10% year-over-year growth, and adjusted EBITDA was $24.1 million, up 35% year-over-year. We continue to effectively leverage our growth drivers, including a significant increase in sales of our anti-rabies immunoglobulin product, KEDRAB and the promotion of CYTOGAM."

User Image Stock_Titan Posted - 2 months ago

$KMDA Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability https://www.stocktitan.net/news/KMDA/kamada-reports-strong-fiscal-year-and-fourth-quarter-2023-financial-377y9xw1u61b.html

User Image Stock_Titan Posted - 02/28/24

$KMDA Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024 https://www.stocktitan.net/news/KMDA/kamada-to-announce-fourth-quarter-and-fiscal-year-2023-financial-djq6176jno0p.html

User Image Doozio Posted - 02/27/24

$KMDA chop chop huckleberries….

User Image Doozio Posted - 01/20/24

$KMDA 3wt holding gap n it’s NOW 2020FOUR 🧠⏰.

User Image TOOL88 Posted - 4 months ago

$TBLA Half of the shares were sold 80% profit and bought $KMDA target after the largest contract ever $10.

User Image cctranscripts Posted - 12/28/23

The Phoenix Holdings Ltd. just provided an update on share ownership of Kamada https://www.conferencecalltranscripts.org/summary/?id=12826486 $KMDA

User Image cctranscripts Posted - 12/28/23

Report of foreign issuer [Rules 13a-16 and 15d-16] https://www.conferencecalltranscripts.org/summary/?id=12826005 $KMDA

User Image Doozio Posted - 12/26/23

$KMDA when a 🧠👀 becomes 🧠⏰. Chop chop huckleberries……

User Image cctranscripts Posted - 12/19/23

The Phoenix Holdings Ltd. just provided an update on share ownership of Kamada https://www.conferencecalltranscripts.org/summary/?id=12803674 $KMDA

User Image MarketBeat Posted - 5 months ago

Kamada downgraded by StockNews.com to hold. www.marketbeat.com/stocks/NASDAQ/KMDA/price-target/ $KMDA

User Image UltraAlgo Posted - 5 months ago

$KMDA Sell rating based off 8 signals on the 15-min chart 🚀 Free Screener at UltraAlgo https://i.redd.it/cd7dxb0cdq4c1.png

User Image StockAutomatePro Posted - 5 months ago

$KMDA The chart is predicting a profitable future for the stock. We alerted the BUY signal at $4.71 and we were able to close this one with profit at $5.88 📊

User Image dividendinvestorbyeagle Posted - 5 months ago

$KMDA close increased > 10% (Ord/Kamada Ltd) https://www.dividendinvestor.com/dividend-news/?symbol=kmda http://dlvr.it/SzrvlY

User Image Buffee Posted - 5 months ago

$KMDA leets go

User Image StockAutomatePro Posted - 5 months ago

$KMDA Stock market is looking optimistic based on the chart. We alerted the BUY signal at $4.78 and we were able to close this one with profit at $5.85 😎

User Image tickeron Posted - 5 months ago

A.I.dvisor made a bullish call on $KMDA, netting in a 14.93% gain over 2 months https://srnk.us/go/4934745

User Image tickeron Posted - 5 months ago

How do you think the market will react to this? $KMDA RSI Indicator left the overbought zone. View odds of downtrend. https://srnk.us/go/4934739

Analyst Ratings
HC Wainwright & Co. Buy May 9, 24
HC Wainwright & Co. Buy Mar 7, 24
HC Wainwright & Co. Buy Nov 14, 23
HC Wainwright & Co. Buy Aug 17, 23
HC Wainwright & Co. Buy May 25, 23
HC Wainwright & Co. Buy Mar 16, 23
Chardan Capital Buy Feb 2, 18
Jefferies Buy Nov 13, 15
Jefferies Buy Jun 25, 13